Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Christopher E. Barbieri
Historically, prostate biopsy was performed using only systematic, template-based sampling.1 Prostate magnetic resonance imaging (MRI) followed by targeted biopsy of lesions suggestive of malignant neoplasm has emerged as a major advance in prostate cancer diagnosis, with several randomized clinical trials establishing superiority over systematic-only approaches.2-4 For men with prior negative biopsy results and persistent concern for cancer, prebiopsy MRI was substantiated even earlier,5...
Isoleucine and valine promote prostate cancer progression via propionyl-CoA-mediated cholesterol metabolism
Abstract Enhanced cholesterol synthesis and lipid droplet accumulation are hallmarks of aggressive prostate cancer, yet how tumour cells sense metabolic inputs to dynamically regulate cholesterol homeostasis remains poorly defined. Here we uncover a metabolic signalling mechanism in which prostate cancer cells remodel propionyl-CoA metabolism to support stress adaptation during disease progression.
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction - Nature Communications
Abstract BPTF, the scaffolding subunit of the nucleosome remodeling factor (NURF) complex, has been implicated in the progression of several malignancies, but its role in prostate cancer (PCa) remains unclear. Here, we demonstrate that BPTF is upregulated in castration-resistant prostate cancer (CRPC) and promotes disease progression. RNA-seq revealed that BPTF primarily enhances the expression of androgen receptor (AR) target genes.
Direct measurement of the male germline mutation rate in individuals using sequential sperm samples - Nature Communications
Abstract Mutations that accumulate in the human male germline with age are a major driver of genetic diversity and contribute to genetic diseases. However, aging-related male germline mutation rates have not been measured directly in germline cells (sperm) at the level of individuals. We developed a study design in which we recalled 23 sperm donors with prior banked samples to provide new sperm samples.
Canonical Androgen Response Elements in Prostate Cancer Growth Suppression - Christopher Barbieri
Read the Full Video Transcript Andrea Miyahira: Hi. I'm Andrea Miyahira at the Prostate Cancer Foundation. With me is Dr. Christopher Barbieri of Weill Cornell Medicine, who will present a recent Nature Communications paper, "Canonical Androgen Response Element Motifs are Tumor Suppressive Regulatory Elements in the Prostate." Thanks, Dr. Barbieri for joining and sharing this. Christopher Barbieri: Thanks. It's a pleasure to be here with you today.
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate - Nature Communications
Abstract The androgen receptor (AR) is central in prostate tissue identity and differentiation, and controls normal growth-suppressive, prostate-specific gene expression. It also drives prostate tumorigenesis when hijacked for oncogenic transcription. The execution of growth-suppressive AR transcriptional programs in prostate cancer (PCa) and the potential for reactivation remain unclear.
Distinct mesenchymal cell states mediate prostate cancer progression - Nature Communications
Abstract In the complex tumor microenvironment (TME), mesenchymal cells are key players, yet their specific roles in prostate cancer (PCa) progression remain to be fully deciphered. This study employs single-cell RNA sequencing to delineate molecular changes in tumor stroma that influence PCa progression and metastasis.
The Molecular Biology of Prostate Cancer - Christopher Barbieri
Read the Full Video Transcript Matthew Cooperberg: Hi, I'm Matt Cooperberg. Welcome to another installment of our live Localized Prostate Cancer Center of Excellence interviews for UroToday.
JAK inhibition shows two faces in prostate cancer - Nature Cancer
Therapeutic resistance in prostate cancer can be driven by lineage plasticity, but the mechanisms behind this are unclear, and therapies to prevent or reverse the process are nonexistent. A new study reveals the JAK/STAT signaling axis as a driver of lineage plasticity with tremendous therapeutic potential. Over the past decade, advances in the mechanistic understanding of prostate cancer biology have led to significant improvements in patient survival.
Race and prostate cancer: genomic landscape - Nature Reviews Urology
Abstract In the past 20 years, new insights into the genomic pathogenesis of prostate cancer have been provided. Large-scale integrative genomics approaches enabled researchers to characterize the genetic and epigenetic landscape of prostate cancer and to define different molecular subclasses based on the combination of genetic alterations, gene expression patterns and methylation profiles.
Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing - Nature Biotechnology
Abstract High-order three-dimensional (3D) interactions between more than two genomic loci are common in human chromatin, but their role in gene regulation is unclear. Previous high-order 3D chromatin assays either measure distant interactions across the genome or proximal interactions at selected targets.
Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study
Adithya Balasubramanian Adithya Balasubramanian Correspondence Correspondence: Affiliations Department of Urology, Weill Cornell Medicine/New York Presbyterian, New York, NY, USA Search for articles by this author Himanshu Nagar Christopher E. Barbieri Scott T. Tagawa Scott T.
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
Precision medicine relies on the deceptively simple principle that specific subsets of patients will be more responsive to specific therapies and that these patients can be identified to allow this tailoring of therapy [ ]. This includes classic targeted therapy, whereby a specific biomolecule is both the therapeutic target and biomarker used to guide treatment decisions.
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations
Genome Biology201718:80DOI: 10.1186/s13059-017-1183-5© The Author(s). 2017Received: 27 February 2017Accepted: 27 February 2017Published: 2 May 2017
DNA Repair in Prostate Cancer: Biology and Clinical Implications
For more precise, personalized care in prostate cancer (PC), a new classification based on molecular features relevant for prognostication and treatment stratification is needed. Genomic aberrations in the DNA damage repair pathway are common in PC, particularly in late-stage disease, and may be relevant for treatment stratification. To review current knowledge on the prevalence and clinical significance of aberrations in DNA repair genes in PC, particularly in metastatic disease.
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics
Biomarker-driven cancer therapy, also referred to as precision oncology, has received increasing attention for its promise of improving patient outcomes by defining subsets of patients more likely to respond to various therapies. In this collaborative review article, we examine recent literature regarding biomarker-driven therapeutics in urologic oncology, to better define the state of the field, explore the current evidence supporting utility of this approach, and gauge potential for the future.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher E.
Contact Christopher E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack